A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Nelotanserin (Primary)
- Indications Dementia; Lewy body disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Axovant Sciences
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2017 According to an Axovant Sciences media release, the Company expects top-line results in fourth quarter 2017.
- 29 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History